Exploring the optimal use of alectinib

Diego Enrico; Christophe Massard; Benjamin Besse

doi:10.1016/S2213-2600(19)30117-1

Exploring the optimal use of alectinib

Diego Enrico, Christophe Massard, Benjamin Besse

Résultats de recherche: Contribution à un journal › !!Comment/debate

2 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	373-374
Nombre de pages	2
journal	The Lancet Respiratory Medicine
Volume	7
Numéro de publication	5
Les DOIs	https://doi.org/10.1016/S2213-2600(19)30117-1
état	Publié - 1 mai 2019

Accès au document

10.1016/S2213-2600(19)30117-1

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{93f21a60f7af46bda75ed3fbd264705e,

title = "Exploring the optimal use of alectinib",

author = "Diego Enrico and Christophe Massard and Benjamin Besse",

note = "Funding Information: DE declares no competing interests. CM receives consultant and advisory fees from Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, and Orion; and is a principal and subinvestigator of clinical trials for AbbVie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveopharmaceuticals, Bayer, Beigene, Blueprint, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GlaxoSmithKline, H3 Biomedicine, Incyte, InnatePharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, LytixBiopharma, Medimmune, Menarini, Merus, Merck Sharp & Dohme, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, PharmaMar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor. BB does research at Gustave Roussy Cancer Center funded by AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Ignyta, Ipsen, Merck, Merck Sharp & Dohme, Nektar, Onxeo, Pfizer, PharmaMar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma.",

year = "2019",

month = may,

day = "1",

doi = "10.1016/S2213-2600(19)30117-1",

language = "English",

volume = "7",

pages = "373--374",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

number = "5",

}

TY - JOUR

T1 - Exploring the optimal use of alectinib

AU - Enrico, Diego

AU - Massard, Christophe

AU - Besse, Benjamin

N1 - Funding Information: DE declares no competing interests. CM receives consultant and advisory fees from Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, and Orion; and is a principal and subinvestigator of clinical trials for AbbVie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveopharmaceuticals, Bayer, Beigene, Blueprint, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GlaxoSmithKline, H3 Biomedicine, Incyte, InnatePharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, LytixBiopharma, Medimmune, Menarini, Merus, Merck Sharp & Dohme, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, PharmaMar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor. BB does research at Gustave Roussy Cancer Center funded by AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Ignyta, Ipsen, Merck, Merck Sharp & Dohme, Nektar, Onxeo, Pfizer, PharmaMar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma.

PY - 2019/5/1

Y1 - 2019/5/1

UR - http://www.scopus.com/inward/record.url?scp=85064669853&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(19)30117-1

DO - 10.1016/S2213-2600(19)30117-1

M3 - Comment/debate

C2 - 31000476

AN - SCOPUS:85064669853

SN - 2213-2600

VL - 7

SP - 373

EP - 374

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 5

ER -